Comparison of the biodistribution of 153Gd-labeled Gd(DTPA)2-, Gd(DOTA)-, and Gd(acetate)n in mice.
The biodistributions of 153Gd-labeled Gd(DTPA)2-, Gd(DOTA)-, and Gd(acetate)n were determined in mice at five residence times. Gd(DTPA)2- and Gd(DOTA)- had similar distributions with greater than 89% renally excreted in 1 h. At 7 days and longer after Gd(DTPA)2- administration, 153Gd bone levels were higher than could be attributed to free 153Gd3+, suggesting that Gd(DTPA)2- dechelates in vivo. Gd(DOTA)- did not appear to dechelate. Gd(acetate)n did not readily clear and 153Gd levels remained high in liver, lungs, and spleen for 28 days.
Wedeking
P
P
Squibb Institute for Medical Research, New Brunswick, NJ 08903.
Tweedle
M
M
D000085:Acetates / Q000378:metabolism*; D000818:Animals; D003287:Contrast Media / Q000378:metabolism*; D005682:Gadolinium / Q000378:metabolism*; D019786:Gadolinium DTPA; D006571:Heterocyclic Compounds / Q000378:metabolism*; D008297:Male; D051379:Mice; D009942:Organometallic Compounds / Q000378:metabolism*; D004369:Pentetic Acid / Q000378:metabolism*; D014018:Tissue Distribution
D000085:Acetates; D003287:Contrast Media; D006571:Heterocyclic Compounds; D009942:Organometallic Compounds; C060927:gadolinium (+3) acetate; D004369:Pentetic Acid; C050823:gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate; D005682:Gadolinium; D019786:Gadolinium DTPA